Objective — Identify whether the prescription sequence of cough suppressant within one year following patients' first ACE‐I prescription can be used as an indicator for the occurrence of ACE‐I associated cough.
Design — Observational retrospective controlled cohort design using all patients receiving ACE‐I as study cohort and patients having prescriptions for hydralazine, clonodine and prazosin as the control. Patient demographics and prescribing indications were controlled statistically using multivariate logistic regression.
Setting — A large computerized clinical database encompassing the medical records of 450,000 patients seen over a 20‐year period at a county medical centre ambulatory clinic.
Patients — 5373 patients exposed to any of captopril, enalapril, lisinopril, clonodine, hydralazine or prazosin.
Main results — This study identified an odds ratio (OR) of 1.53 [95% confidence interal (CI) 1.17 to 2.01] for receipt of an antitussive following patients' first ACE‐I prescription. Other significant risk factors included female gender [OR = 1.52, CI 1.13 to 2.07] and diagnosis of congestive heart failure [OR = 1.47, CI 1.10 to 1.94].
Conclusion — The receipt of an antitussive following ACE‐I prescription may be used to monitor for ACE‐I associated cough, although its utility is unknown.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.